**Author details**

Natalia Zambudio Carroll1 \*, Betsabé Reyes2 and Laureano Vázquez<sup>1</sup>

\*Address all correspondence to: nataliazambudio@gmail.com

1 Department of Surgery, Hospital San Agustín, Linares, Spain

2 Department of Surgery, Hospital Nuestra Señora de la Candelaria, Tenerife, Spain

#### **References**


[6] Farrell JJ. Prevalence, diagnosis and management of pancreatic cystic neoplasms: current status and future directions. Gut Liver. 2015 Sep;9(5):571–89.

the surveillance interval if no changes are detected after several years. If there is another

• Invasive carcinoma: studies say that the risk of IPMN recurrence is 25–50% [62], and it recommended surveillance every 6 months [28]. If we diagnose patients, a recurrence of

We would like to recognize the work of Doreen Carroll helping with the reviewing and editing

\*, Betsabé Reyes2 and Laureano Vázquez<sup>1</sup>

[1] Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang J-Y, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the

[2] Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: Differences in clinical characteristics and surgical

[3] Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J

[4] Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the

[5] Grützmann R, Post S, Saeger HD, Niedergethmann M. Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis. Dtsch Ärztebl

2 Department of Surgery, Hospital Nuestra Señora de la Candelaria, Tenerife, Spain

nonresected IPMN, follow-up should continue as stated above [23, 61].

of the article, and Dr. Lidia Alcalá Mata for the help obtaining MRCP images.

\*Address all correspondence to: nataliazambudio@gmail.com 1 Department of Surgery, Hospital San Agustín, Linares, Spain

pancreas. Pancreatology. 2012:12(3):183–97.

management. Arch Surg. 1999 Oct 1;134(10):1131–6.

Surg Pathol [Internet]. 2000;24(10):1374–1375.

pancreas. Gut. 2011 Apr 1;60(4):509–16.

Int. 2011 Nov;108(46):788–94.

IPMN will need EUS for evaluation.

**Acknowledgements**

86 Challenges in Pancreatic Pathology

**Author details**

**References**

Natalia Zambudio Carroll1


[32] Michaels PJ, Brachtel EF, Bounds BC, Brugge WR, Bishop Pitman M. Intraductal papillary mucinous neoplasm of the pancreas. Cancer Cytopathol. 2006 Jun 25;108(3):163–73.

[20] Sahani DV, Lin DJ, Venkatesan AM, Sainani N, Mino-Kenudson M, Brugge WR, et al. Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas. Clin Gastroenterol Hepatol. 2009 Mar;7(3):259–69.

[21] Yoon WJ, Brugge WR. Pancreatic cystic neoplasms: diagnosis and management. Mod

[22] Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL. Cystic

[23] Salvia R, Castillo CF, Bassi C, Thayer SP, Falconi M, Mantovani W, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy

[24] Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004

[25] Capurso G, Boccia S, Salvia R, Del Chiaro M, Frulloni L, Arcidiacono PG, et al. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre

[26] Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, Al-Haddad MA, et al. Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic

[27] Weinberg BM, Spiegel BM, Tomlinson JS, Farrell JJ. Asymptomatic pancreatic cyst neoplasms: maximizing survival and quality of life using markov-based clinical nomo-

[28] Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Jang J-Y, Kimura W, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the

[29] American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. Vege V, Ziring B, Jain R,

[30] Nguyen AH, Toste PA, Farrell JJ, Clerkin BM, Williams J, Muthusamy VR, et al. Current recommendations for surveillance and surgery of intraductal papillary mucinous neoplasms may overlook some patients with cancer. J Gastrointest Surg Off J Soc Surg

[31] Ridtitid W, DeWi JM, Schmidt CM, Roch A, Stuart JS, Sherman S, et al. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes. Gastrointest Endosc. 2016

and long-term survival following resection. Ann Surg. 2004 May;239(5):678–87.

neoplasms of the pancreas. N Engl J Med. 2004 Sep 16;351(12):1218–26.

case-control study. Am J Gastroenterol. 2013 Jun;108(6):1003–9.

disease? Am J Surg. 2016 Mar;211(3):512–8.

pancreas. Pancreatology. 2012;12:183–97.

et al. Gastroenterology 2015;148:819–822

Aliment Tract. 2015 Feb;19(2):258–65.

Sep;84(3):436–45

grams. Gastroenterology. 2010 Feb;138(2):531–40.

Manag Benign Malig Pancreat Dis. 2012 Mar;41(1):103–18.

Jun;239(6):788–99.

88 Challenges in Pancreatic Pathology


[56] McMillan MT, Lewis RS, Drebin JA, Teitelbaum UR, Lee MK, Roses RE, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016 Feb 15;122(4):521–33.

[44] TanakaM, Chari S,Adsay V, Carlos Castillo F-D, FalconiM, ShimizuM, et al.International consensus guidelines for management of intraductal papillary mucinous neoplasms and

[45] Vege SS, Ziring B, Jain R, Moayyedi P, Adams MA, Dorn SD, et al. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr;148(4):819–22.

[46] Das A, Wells CD, Nguyen CC. Incidental cystic neoplasms of pancreas: what is the optimal interval of imaging surveillance [quest]. Am J Gastroenterol. 2008 Jul;103(7):1657–62.

[47] Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, et al. Managing incidental findings on abdominal CT: White Paper of the ACR Incidental

[48] Tanaka M. Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol

[49] Hwang DW, Jang J-Y, Lee SE, Lim C-S, Lee KU, Kim S-W. Clinicopathologic analysis of surgically proven intraductal papillary mucinous neoplasms of the pancreas in SNUH: a 15-year experience at a single academic institution. Langenbecks Arch Surg.

[50] Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003

[51] Scheiman JM, Hwang JH, Moayyedi P. American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic

[52] Jang J-Y, Kim S-W, Ahn YJ, Yoon Y-S, Choi MG, Lee KU, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124–32.

[53] Crippa S, Tamburrino D, Partelli S, Salvia R, Germenia S, Bassi C, et al. Total pancreatectomy: indications, different timing, and perioperative and long-term outcomes. Surgery.

[54] Stauffer JA, Nguyen JH, Heckman MG, Grewal MS, Dougherty M, Gill KRS, et al. Patient outcomes after total pancreatectomy: a single centre contemporary experience. HPB.

[55] Swartz MJ, Hsu CC, Pawlik TM, Winter J, Hruban RH, Guler M, et al. Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys. 2010 Mar

Findings Committee. J Am Coll Radiol. 2010 Oct;7(10):754–73.

Hepatol. 2011 Jan;8(1):56–60.

2012;397(1):93–102.

90 Challenges in Pancreatic Pathology

Oct 1;90(10):1244–9.

2011 Jan;149(1):79–86.

2009 Sep;11(6):483–92.

1;76(3):839–44.

cysts. Gastroenterology. 148(4):824–48.e22.

mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6(1–2):17–32.


### **Management of Pancreatic Cystic Lesions Management of Pancreatic Cystic Lesions**

Vincenzo Neri Vincenzo Neri

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/65117

#### **Abstract**

**Objectives:** In the last several decades, the knowledge of the cystic neoplasms has enlarged and the management has changed. The wide adoption in the diagnostic procedures of routine and advanced imaging has become the cornerstone of the diagnosis.

**Methods:** Pancreatic cystic tumors comprise neoplasms with a wide range of malignant potential. The most common include serous cystic neoplasm, mucinous cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs), solid pseudopapillary neoplasms (SPPNs), and cystic pancreatic endocrine neoplasms (CPENs). Other cystic lesions are acute postnecrotic pseudocysts and chronic pseudo‐ cysts. Finally, the indeterminate cystic lesions have been presented.

**Results:** The epidemiology, pathological features, imaging characteristics, clinical evolution, and therapeutic choices of the most frequent lesions as well as less frequent forms are described. This study can be completed with the presentation of some cases of cystic pancreatic neoplasms treated in our service.

**Conclusion:** The improvement ofimaging, endoscopic modalities, and cyst fluid studies allows now accurate and reliable diagnosis of pancreatic cystic lesions. Moreover, the enlarged knowledge of valuable pathological studies established the potential for malignant transformation of these lesions identifying higher‐risk neoplasms. Finally, the management options should be based on the assessment of each type of cystic neoplasms and the distinction of pancreatic cystic neoplasms (PCNs) from other cystic lesions.

**Keywords:** cystic pancreatic lesions, pancreas, pseudocysts, pancreatitis, indetermi‐ nate pancreatic cystic lesions

© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
